Menu

Monsanto and Bayer Announce Approval of Massive Merger

On Tuesday, shareholders at the agribusiness giant approved the $66 billion deal with the European pharmaceutical firm.

Dec 13, 2016
Bob Grant

WIKIMEDIA, LARS PLOUGHMANNIn a move that has been anticipated for months, agribusiness corporation Monsanto has taken another step towards finalizing a $66 billion merger with Bayer AG, the Germany-based pharma and chemical firm. On Tuesday (December 13) Monsanto’s shareholders overwhelmingly approved the $128 per share price paid by Bayer for the acquisition.  The new entity will represent the world’s largest agriculture and chemical company.

“This is a really significant milestone,” Monsanto CEO Hugh Grant told the St. Louis Post-Dispatch. “When you get 99 percent affirmation, that's very encouraging.”

But outside of the 99 percent of Monsanto shareholders who approved the deal, one individual filed a lawsuit to stop it, alleging that the shares were worth more than $128 a piece. That suit was thrown out by a St. Louis County judge.

The National Farmers Union has also spoken out against the deal. “Consolidation of this magnitude cannot be the standard for agriculture, nor should we allow it to determine the landscape for our future,” the organization said in a statement posted in September, when the merger was first announced. The Natural Resources Defense Council (NRDC) sent a letter on December 12 to the Department of Justice, also opposing the merger. “While, standing alone, a proposal for the takeover of the world's largest producer of genetically modified seeds by the world's second largest producer of pesticides is problematic, it is also part of a troubling trend of consolidation in the agricultural sector,” the letter read. Rebecca Riley, senior attorney in the Natural Resources Defense Council’s (NRDC) Land & Wildlife program, also railed against the merger. “If you are a farmer, consumer, or any of the pollinators critical to our nation’s food supply—such as the bees and monarch butterflies facing massive new threats from pesticides in recent years—this big business merger could be very bad news,” she wrote in a blog post on the NRDC’s website.

The deal is expected to close at the end of 2017, after anti-trust regulators in the U.S. Europe, Brazil, India, and China review and OK it.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.